Patent · US Expired

Method for treating multi-drug resistant tumors

US7303760B2 · kind B2 · utility

3Cited by
19References
10Claims
0Family size

Assignees

Inventors

Key dates

Filing dateNov 14, 2003
Grant dateDec 4, 2007
Priority date
Expiry dateJan 11, 2026

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.